NurExone Biologic Inc.
NRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.47M | -1.85M | -1.68M | -1.55M | -1.25M |
| Total Depreciation and Amortization | 47.00K | 42.00K | 43.00K | 39.00K | 18.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 329.00K | 313.00K | 313.00K | 333.00K | 316.00K |
| Change in Net Operating Assets | -195.00K | 424.00K | 336.00K | -561.00K | 98.00K |
| Cash from Operations | -1.28M | -1.07M | -986.00K | -1.74M | -818.00K |
| Capital Expenditure | -12.00K | -2.00K | -32.00K | -46.00K | -301.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 1.00K | 0.00 |
| Cash from Investing | -12.00K | -2.00K | -32.00K | -45.00K | -301.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.00K | -1.00K | -3.00K | -7.00K | -8.00K |
| Issuance of Common Stock | 1.07M | 1.59M | 913.00K | 1.46M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -44.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1.28M | 1.31M |
| Cash from Financing | 1.06M | 1.59M | 910.00K | 177.00K | 1.26M |
| Foreign Exchange rate Adjustments | -11.00K | 119.00K | -4.00K | -220.00K | -2.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -245.00K | 640.00K | -112.00K | -1.82M | 138.00K |